Chelsea Manalese
Family · Glendale, AZNPI 1033878921
Payments from drug & device makers
Across 96 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$433
- AbbVie$261
- Novo Nordisk$258
- Lilly USA, LLC$189
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$117
- Organon$98
- plus $711 from 21 others
What the payments were for
- Food & beverage$2,01998%
- Education$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $433 |
| AbbVie | 13 | $261 |
| Novo Nordisk | 24 | $258 |
| Lilly USA, LLC | 6 | $189 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $117 |
| Organon | 1 | $98 |
| Boehringer Ingelheim | 5 | $81 |
| Intra-sana Laboratories | 2 | $65 |
| Amgen | 4 | $64 |
| Abbott | 3 | $63 |
| Novartis | 3 | $48 |
| OPKO Pharmaceuticals, LLC | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Lucid Diagnostics Inc. | 1 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| GSK | 2 | $31 |
| Exact Sciences | 1 | $30 |
| Insulet Corporation | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Optos, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,067 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $13,874 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $589 |
| Potassium Chloride | 15 | $583 |
| Omeprazole | 23 | $450 |
| Levothyroxine Sodium | 40 | $433 |
| Losartan Potassium | 32 | $433 |
| Atorvastatin Calcium | 46 | $384 |
| Duloxetine Hcl | 13 | $353 |
| Metformin Hcl | 35 | $349 |
| Metoprolol Succinate | 21 | $286 |
| Gabapentin | 16 | $241 |
| Tamsulosin Hcl | 15 | $240 |
| Lisinopril | 41 | $198 |
| Rosuvastatin Calcium | 18 | $187 |
| Montelukast Sodium | 17 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $433 | $13,87412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.
Other family in Glendale
- Kelci HunterGlendale$19K
- Amber BerleenGlendale$16K
- Ashley SchohnGlendale$16K
- Bettina SiebeneckGlendale$15K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.